Ticker: PASG

Snapshot - Passage Bio, Inc. (PASG) (NASDAQ) What's happening inside: the company executed a major restructuring in Jan 2025 (≈55% workforce reduction) and ceased Hopewell lab operations, out‑licensed several pediatric lysosomal programs to Gemma, and is concentrating resources on its lead clinic...

Company Overview: Passage Bio, Inc. (NASDAQ: PASG) is a clinical-stage genetic medicines company focused on developing therapies for neurodegenerative diseases. Recent Developments: As of March 31, 2025, the company reported an accumulated deficit of $674.6 million. Cash and cash equivalents amo...